Tenax Therapeutics, Inc. (TENX) ended last trading session with a change of 1.3 percent. It trades at an average volume of 1.1M shares versus 3.36M shares recorded at the end of last trading session. The share price of $0.72 is at a distance of 73.16 percent from its 52-week low and down -75.56 percent versus its peak. The company has a market cap of $22.8M and currently has 31.73M shares outstanding. The share price is currently -61.84 percent versus its SMA20, -62.99 percent versus its SMA50, and -68.05 percent versus its SMA200. The stock has a weekly performance of -63.15 percent and is -63.15 percent year-to-date as of the recent close.

On January 31, 2017 Tenax Therapeutics, Inc. (TENX) announced top-line results from its Phase 3 LEVO-CTS trial. The study did not achieve statistically significant reductions in the dual endpoint of death or use of a mechanical assist device at 30 days, nor in the quad endpoint of death, myocardial infarction, need for dialysis, or use of a mechanical assist device at 30 days. However, the study demonstrated statistically significant reductions in two of three secondary endpoints including reduction in low cardiac output syndrome (LCOS) and a reduction in postoperative use of secondary inotropes. Patient visits for data on death through day 90 have not yet been completed. The Company has a meeting scheduled with the U.S. Food and Drug Administration (FDA) to review the preliminary trial data and discuss a path forward to bring this potentially lifesaving treatment to the benefit of patients undergoing serious cardiac surgery.

Intrexon Corporation (XON) recently recorded -2.77 percent change and currently at $21.43 is 5.1 percent away from its 52-week low and down -46.74 percent versus its peak. It has a past 5-day performance of 2.05 percent and trades at an average volume of 1.34M shares. The stock has a 1-month performance of -17.03 percent and is -11.81 percent year-to-date as of the recent close. There were about 118.35M shares outstanding which made its market cap $2.54B. The share price is currently -7.68 percent versus its SMA20, -17.93 percent versus its SMA50, and -19.97 percent versus its SMA200.

On Jan. 24, 2017 Intrexon Corporation (XON) announced that it has entered into a definitive agreement to acquire GenVec, Inc. (GNVC), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology.

Intrexon intends to integrate and expand upon GenVecs expertise in adenoviral vectors and cGMP drug product manufacturing to enhance its broad gene transfer capabilities that encompass multiple viral and non-viral platforms. Notably, the combined technologies have the potential to yield the next generation of adenoviral (AdV) delivery through the creation of a scalable manufacturing platform utilizing helper-dependent adenovirus with significantly higher payload capacity of >30kb, as compared to current viral delivery methods ranging from 4.5kb 9kb.

More:
Top Biotechnology Stock Picking: Tenax Therapeutics, Inc. (TENX ... - The Independent Republic